MDFA’s Low Vision report highlights the evidence base supporting the benefits of aids and technologies for those with vision loss and blindness.
Read MoreMDFA’s Low Vision report highlights the evidence base supporting the benefits of aids and technologies for those with vision loss and blindness.
Read MorePeople living in rural and remote areas needing sight-saving treatment will benefit from an important procedural change.
Read MoreGrand finalist and category winners of the mEYE World Photographic Competition 2016 announced to mark World Diabetes Day.
Read MoreMDFA welcomes news that Ozurdex will be listed on the Pharmaceutical Benefits Scheme (PBS) from November 2016.
Read MoreSusan regrets not having regular eye tests. If her diabetic eye disease was picked up earlier, she may not have lost her sight.
Read MoreMacular Disease Foundation Australia has responded to the Independent Review of the NDIS Act.
Read MoreMDFA says the addition of ranibizumab (Lucentis) to the Pharmaceutical Benefits Scheme provides patients with affordable access to treatment for diabetic macular oedema and retinal vein occlusion.
Read MoreMDFA has voiced its concern regarding the economic impact of diabetic macular oedema (DMO) in Australia.
Read More